Division of Infectious Diseases, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, South Korea.
Division of Infectious Diseases, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea.
Antimicrob Resist Infect Control. 2021 Jul 22;10(1):108. doi: 10.1186/s13756-021-00980-1.
Sequence type (ST) 17 vancomycin-resistant Enterococcus faecium (VREF) is frequently isolated in nosocomial settings. The aim of this study was to identify whether ST17 contributes to subsequent bacteremia more often than other STs among hospitalized patients carrying VREF.
A retrospective cohort study was conducted in patients carrying ST17 VREF and those with non-ST17 VREF. Rectal screening according to hospital policy was used to identify patients with VREF. Subsequent VREF bacteremia events within a year of detection of colonization were recorded. Cox regression analysis was used to adjust the covariates involved in determining the association between ST17 and subsequent bacteremia events.
The cohorts comprised 52 patients with ST17 and 169 patients with non-ST17 VREF. One-year VREF bacteremia-free rates were 85.9% and 90.2%, respectively. In multivariate analysis, ST17 was associated with subsequent bacteremia at an adjusted hazard risk (aHR) of 4.02 (95% confidence interval [CI], 1.32-12.29). Liver transplantation (aHR, 40.08; 95% CI, 4.87-329.76) and hematologic malignancy (aHR, 20.97; 95% CI, 4.87-87.82) were also significant. All cases of subsequent bacteremia in ST17 VREF carriers were caused by ST17; however, subsequent bacteremia in non-ST17 carriers was often caused by ST17 or another ST variant.
A specific genotype, ST17 is a predictor of subsequent bacteremia in hospitalized patients carrying VREF. Patients with a hematologic malignancy and those receiving a liver transplant are also at high risk. More targeted strategies may be needed to prevent VREF infection in hospitals.
序列类型(ST)17 万古霉素耐药粪肠球菌(VREF)在医院环境中经常被分离出来。本研究的目的是确定在携带 VREF 的住院患者中,ST17 是否比其他 ST 更频繁地导致随后的菌血症。
对携带 ST17 VREF 和非 ST17 VREF 的患者进行回顾性队列研究。根据医院政策进行直肠筛查以确定 VREF 患者。在检测定植后一年内记录随后发生的 VREF 菌血症事件。Cox 回归分析用于调整确定 ST17 与随后菌血症事件之间关联的相关因素。
队列包括 52 例 ST17 患者和 169 例非 ST17 VREF 患者。1 年 VREF 菌血症无事件率分别为 85.9%和 90.2%。多变量分析显示,ST17 与随后的菌血症相关,调整后的危险比(aHR)为 4.02(95%置信区间 [CI],1.32-12.29)。肝移植(aHR,40.08;95%CI,4.87-329.76)和血液恶性肿瘤(aHR,20.97;95%CI,4.87-87.82)也是显著的。ST17 VREF 携带患者所有随后的菌血症均由 ST17 引起;然而,非 ST17 携带患者的随后菌血症通常由 ST17 或另一种 ST 变体引起。
特定基因型 ST17 是携带 VREF 的住院患者随后发生菌血症的预测因子。患有血液恶性肿瘤和接受肝移植的患者也处于高风险中。可能需要更有针对性的策略来预防医院内 VREF 感染。